Vaccine Controversies & Concerns, Answered
COVID Vaccine Myocarditis: How Big Is the Risk?
Of all the claims in this section, covid vaccine myocarditis risk is the one with a real signal underneath it. Myocarditis — inflammation of the heart muscle — does occur after mRNA COVID-19 vaccination, rarely, mostly in young males. This page gives the rates per million doses, the honest comparison with myocarditis after COVID-19 infection (including the one subgroup where the comparison runs the other way), and what follow-up of patients shows.
The claim
“The COVID-19 vaccines are causing an epidemic of heart inflammation and sudden deaths in young men — a risk far worse than the virus, and one officials concealed.” The opposite claim is also made: “There is no heart risk at all.” Both are wrong, in opposite directions.
What is established
Myocarditis and pericarditis after mRNA COVID-19 vaccination were first flagged through the VAERS reporting system in spring 2021 (see our VAERS page), then confirmed and quantified in health-record systems that can calculate real rates. The pattern has been consistent across the US, Israel, England and the Nordic countries: cases cluster in males in their teens and twenties, usually within a week of vaccination, and most often after the second dose of the original two-dose series.
The rates, per million doses
- FDA label data (2023–2024 formula): estimated rates of myocarditis and/or pericarditis in the week after a dose were approximately 8 cases per million doses in people aged 6 months to 64 years overall, and approximately 27 cases per million doses in males aged 12 to 24 — the highest-risk group.
- England, ~43 million people (Patone et al., Circulation, 2022): in men under 40, estimated extra cases per million were about 4 after a first Pfizer dose, 14 after a first Moderna dose, and 97 after a second Moderna dose — the highest vaccine-associated estimate in the study, and one reason several countries moved young men to longer dose intervals or a preferred product. In women aged 40 and over, the figures were about 3 extra cases per million after a first Pfizer dose and 2 per million after a booster.
- More recent formulas: the CDC’s Vaccine Safety Datalink had not detected a statistical signal for myocarditis after the 2024–2025 formula as of March 2025 (reported to the Advisory Committee on Immunization Practices in April 2025), consistent with rates falling as intervals lengthened and the highest-risk dosing patterns changed.
The comparison with COVID-19 infection — stated honestly
In the same English study, people who caught COVID-19 before vaccination were about 11 times more likely to develop myocarditis in the 28 days after infection than people were in the weeks after vaccination, and infection carried an estimated 51 extra cases per million in women over 40. Across most groups, infection is the larger myocarditis risk — and vaccination also reduces the chance of the infection that carries it.
Honesty requires the exception: in men under 40 in that study, the estimate after a second Moderna dose (about 97 extra cases per million) exceeded the estimate after infection in unvaccinated men of the same age (about 16 per million). That single comparison does not describe other doses, other products or other age groups — but it is real, it is in the data, and it is part of why guidance for young men changed. A page that quotes only the reassuring half of this study would not be worth your trust.
What happens to the patients
Most vaccine-associated myocarditis cases responded well to medicine and rest and felt better quickly (CDC). In the CDC’s follow-up study of adolescents and young adults (Kracalik et al., The Lancet Child & Adolescent Health, 2022), about 81% of patients were considered fully or probably recovered by their providers at least 90 days after onset. In the companion patient survey, about half reported at least one lingering symptom at 90 days or more — a reminder that “mostly mild” is not “trivial” for the person affected. Longer-term follow-up studies are continuing. Myocarditis from COVID-19 infection itself tends to occur in sicker patients, alongside the other cardiac complications of the infection.
Chest pain, shortness of breath or a racing or pounding heartbeat in the week after vaccination are symptoms to have checked promptly — that advice is on the FDA label and in CDC guidance.
Current recommendations
US COVID-19 vaccine recommendations have shifted since the original rollout toward individual-based decision-making for younger and lower-risk people. The current season’s recommendations, product by product, are kept up to date in our COVID-19 vaccine guide. For heart conditions and heart symptoms generally, see the conditions library.
What the CDC and FDA say
CDC: myocarditis and pericarditis after COVID-19 vaccination are rare; rates are highest among males in their late teens and early twenties, usually after the second dose; most patients responded well to medicine and rest and felt better quickly. The CDC’s assessment has been that the benefits of mRNA COVID-19 vaccination outweigh the risk of myocarditis in the groups for whom it is recommended, and recommendations have been refined by age and risk over time.
FDA: the risk is carried as a warning on the mRNA vaccine labels, with the per-million rates quoted above — the opposite of concealment: the signal was detected in public reporting systems, quantified in the open literature, and printed on the label.
Bottom line
Myocarditis after mRNA vaccination is a real, documented risk — uncommon, concentrated in young males after the early doses, on the order of tens of cases per million doses in the highest-risk group, and usually resolving. COVID-19 infection carries a larger myocarditis risk for most people, with one honestly-reported exception in the English data for young men after a second Moderna dose. That is the whole picture; be wary of any source — in either direction — that shows you only half of it.
Related concerns
More in this section: the Vaccine Controversies & Concerns hub. For the vaccines themselves, see the Vaccines & Immunization section.
Frequently asked questions
How common is myocarditis after the COVID vaccine?
Uncommon. FDA label estimates for the 2023–2024 formula were about 8 cases per million doses across ages 6 months to 64 years, and about 27 per million doses in the highest-risk group, males aged 12 to 24, in the week after a dose. In the large English study, the highest vaccine-associated estimate was about 97 extra cases per million in men under 40 after a second Moderna dose.
Who is most at risk of vaccine myocarditis?
Males in their teens and twenties, usually within a week of vaccination and most often after the second dose of the original series. Cases in women, older adults and young children occur but at much lower rates. Later vaccine formulas and longer dose intervals have been associated with lower rates; the CDC’s Vaccine Safety Datalink detected no statistical signal for the 2024–2025 formula as of March 2025.
Is myocarditis more common after COVID infection or after the vaccine?
For most groups, after infection. In the English study of ~43 million people, infection before vaccination carried about 11 times the myocarditis risk of the post-vaccination period overall. The exception in that study: in men under 40, a second Moderna dose carried a higher estimate (about 97 per million) than infection in unvaccinated men of the same age (about 16 per million).
Do people recover from myocarditis after vaccination?
Mostly, yes. The CDC reports most patients responded well to medicine and rest and felt better quickly. In CDC follow-up of adolescents and young adults, about 81% were considered fully or probably recovered by their providers at 90 days or more; about half of surveyed patients reported at least one lingering symptom, and longer-term follow-up is continuing.
What symptoms after vaccination should be checked urgently?
Chest pain, shortness of breath, or feelings of a fast-beating, fluttering or pounding heart in the days after vaccination — seek medical care promptly. These are the symptoms the FDA label and CDC guidance tell vaccine recipients to watch for, particularly in the first week.
Sources named on this page
- Patone M et al., Circulation, 2022 — England, ~43 million people: extra myocarditis cases per million after vaccination and after SARS-CoV-2 infection, by age, sex, product and dose.
- FDA prescribing information for mRNA COVID-19 vaccines (2023–2024 formula) — estimated rates ~8 per million doses overall; ~27 per million in males 12–24.
- Kracalik I et al., The Lancet Child & Adolescent Health, 2022 — CDC follow-up of myocarditis after mRNA vaccination in 12–29-year-olds; ~81% recovered at ≥90 days (provider assessment).
- CDC, “Myocarditis and Pericarditis After COVID-19 Vaccination” and ACIP workgroup data, April 2025 (Vaccine Safety Datalink, 2024–2025 formula).
This page is general information only. It is not medical advice, and it does not make a recommendation for or against any vaccine for you or your child. Vaccination decisions are personal and belong with your own clinician, who knows your history. If you or your child has had a serious reaction to a vaccine, or has a condition or treatment that weakens the immune system, discuss vaccination with your care team before any dose.